Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

Journal of Hypertension

Volumn 24, Issue 10, 2006, Pages 2047-2055

  Bakris, George L ^a   Ruilope, Luis M ^b   McMorn, Stephen O ^c   Weston, Wayde M ^c   Heise, Mark A ^c   Freed, Martin I ^d   Porter, Lisa E ^e  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c GLAXOSMITHKLINE   (United States)

^d Vitae Pharmaceuticals   (United States)

^e AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Ambulatory blood pressure; Biomarkers; Microalbuminuria; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLIBENCLAMIDE; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SPIRONOLACTONE; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

EID: 33748556888     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000244955.39491.88     Document Type: Article

References (34)

1. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
3. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225-232.
4. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418.
5. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003; 13:144-148.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
7. Dormandy JA, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
8. Bakris G, Viberti G, Weston W, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003; 17:7-12.
9. Oshinyemi K, Garcia S, Curtis P, Zambanini A, Stewart MW. Evaluation of the effects of rosiglitazone combination therapy on ambulatory blood pressure after 6 months; a 12 month substudy of the RECORD trial in people with Type 2 diabetes mellitus [abstract]. Diabetologia 2004; 47:A262.
10. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26:172-178.
11. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27:2654-2660.
12. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-684.
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28(Suppl 1):S37-S42.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
15. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939-946.
16. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000; 36:430-435.
17. Ozdemir G, Ozden M, Maral H, Kuskay S, Cetinalp P, Tarkun I. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. Ann Clin Biochem 2005; 42:99-104.
18. Rowley K, O'Dea K, Su Q, Jenkins AJ, Best JD. Low plasma concentrations of diet-derived antioxidants in association with microalbuminuria in indigenous Australian populations. Clin Sci (Lond) 2003; 105:569-575.
19. Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy - relevance to renoprotection. Nat Clin Pract Nephrol 2005; 1:33-43.
20. Hansson L. The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996; 14:537-544.
21. Viberti G. Prognostic significance of microalbuminuria. Am J Hypertens 1994; 7:S69-S72.
22. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
23. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342.
24. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45:S23-S28.
25. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting. Diabetes Res Clin Pract 2005; 70:90-97.
26. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695-1702.
27. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005; 21:2029-2035.
28. Rosenstock J, Goldstein B, Vinik AI, O'Neill MC, Porter LE, Heise MA, et al. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (> 60 years): the Rosiglitazone Early vs. SULfonylurea Titration (RESULT) study. Diabetes Obes Metab 2006; 8:49-57.
29. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86:280-288.
30. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5:163-170.
31. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108:2941-2948.
32. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48:1726-1735.
33. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25:1737-1743.
34. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003; 107:636-642.